


Cooperation on identification and prioritization of health technologies for joint work



www.efpia.eu

The European Pharmaceutical Industry and Horizon Scanning

- **EFPIA** supports healthcare systems in their efforts to better prepare for the introduction of innovative technologies and faster access for patients. Horizon scanning can be an important tool in this respect.
- **Horizon scanning should build on clear principles, transparent processes, and full** interaction with all relevant stakeholders, including the industry as the primary provider of information on products pre authorisation.
- **Successful horizon scanning systems, e.g. in Sweden and the UK, build on close** collaboration between public authorities and the industry. Continuing dialogue and mutual trust are essential prerequisites for productive horizon scanning.
- An international mechanism for horizon scanning should strive for reducing * duplication through consolidating geography-agnostic data, while national systems are needed to conduct national specific assessments (including impact on health systems, budget impact, local disease burden).



Identification & prioritization of health technologies for joint work

- What is the role of horizon scanning / prioritisation in the future permanent * system? Proposal foresees that all centrally authorised products will be assessed
- During JA3 and in the transition phase, some **prioritisation** is foreseen in order to * support the Coordination Group/ EUnetHTA Executive Board in the scale up of assessment capabilities and capacity
- Prioritisation needs to be based on criteria that are unbiased and based on clinical * considerations, eg
 - unmet medical needs, where there is no treatment or only unsatisfactory treatment * available
 - potential impact on patients and public health, considering, inter alia, the burden of disease measured by mortality and morbidity, and the life-threatening or chronically debilitating nature of the disease targeted by the health technology
 - ***** significant cross-border dimension
 - * the available resources of the Coordination Group
- Prioritisation by the Coordination Group/EUnetHTA Executive Board needs to be * closely linked to a commitment to use the EUnetHTA report
- Voluntary submissions need to be possible
- **Early dialogue** must remain an option for all centrally approved products efpia

Experience with EPL and considerations moving forward

EUnetHTA Prioritisation List

- Importance of transparent and inclusive process at every step of prioritisation *
- Need to plan for validation step with industry before publication *

Implementation considerations – discussion points

- ***** Who?
 - * Which stakeholders should be involved in overall process?
 - * Companies: who will manage the new process? (R&D, Operations)

***** What?

- * Shared data / information needs to be aligned with the purpose (priorities) of the system
- ***** Confidentiality

***** When?

- ***** Process efficiency
- ***** Frequency/updates
- * Rate of attrition in clinical development; timing will impact workload
- * Uncertainty over later stage clinical results / impact







www.efpia.eu * info@efpia.eu